10-Q: Scholar Rock Faces FDA Delay for SMA Drug Apitegromab

Scholar Rock reported increased losses and a significant FDA Complete Response Letter for its lead SMA drug apitegromab, while securing additional debt financing and extending its cash runway into 2027.

Summary

• Reported a net loss of $102.2 million for the three months ended September 30, 2025, up from $64.5 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $287.0 million, compared to $179.8 million for the same period in 2024.
• Received a Complete Response Letter (CRL) from the FDA in September 2025 for apitegromab's Biologics License Application (BLA) due to observations at a third-party fill-finish facility, delaying potential commercialization.
• The CRL was site-related and did not cite concerns regarding apitegromab's efficacy, safety data, or the drug substance manufacturer.
• Completed a constructive Type A meeting with the FDA in November 2025 and plans to resubmit the BLA once the facility is reclassified.
• Submitted and received validation for a marketing authorisation application (MAA) for apitegromab in SMA to the European Medicines Agency (EMA) in March 2025.
• Cash, cash equivalents, and marketable securities totaled $369.6 million as of September 30, 2025, down from $437.3 million at December 31, 2024.
• Secured $50.0 million from a third tranche of its Amended and Restated Loan and Security Agreement with Oxford Finance LLC in September 2025, bringing total outstanding debt to $100.0 million.
• Extended its cash runway into 2027 based on current operating model and existing capital.
• General and administrative expenses significantly increased by 230.4% to $53.1 million for the three months and 170.4% to $131.2 million for the nine months ended September 30, 2025, primarily due to investments in commercialization infrastructure for apitegromab and leadership change-related costs.
• Research and development expenses increased by 3.6% to $50.5 million for the three months and 20.4% to $161.6 million for the nine months ended September 30, 2025, driven by drug supply manufacturing and the initiation of the Phase 2 OPAL trial, partially offset by completion of other trials.
• Positive top-line results from the Phase 2 EMBRAZE trial of apitegromab in obesity showed 54.9% preservation of lean mass (+4.2 lbs) versus tirzepatide alone (p=0.001).
• Completed the Phase 1 DRAGON trial for SRK-181 in cancer, showing encouraging responses in resistant tumors.
• Investigational New Drug (IND) application for SRK-439 cleared by the FDA in September 2025, with dosing in healthy volunteers planned for Q4 2025.

Sentiment

Score: 4

Explanation: While there are positive clinical trial results and an extended cash runway, the significant increase in net losses and the FDA's Complete Response Letter for the lead product candidate, apitegromab, introduce substantial uncertainty and delay for commercialization. The increased G&A expenses for commercialization readiness, now facing a delay, also weigh on the sentiment.

Positives

• Positive top-line results from the SAPPHIRE Phase 3 clinical trial for apitegromab in non-ambulatory SMA patients, achieving its primary endpoint.
• Apitegromab received Priority Review designation from the FDA, Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug designation from the FDA, as well as PRIME and Orphan Medicinal Product designation from the EMA.
• Marketing authorization application (MAA) for apitegromab for SMA was submitted to and validated by the EMA.
• Positive top-line results from the Phase 2 EMBRAZE trial for apitegromab in obesity, demonstrating 54.9% preservation of lean mass (+4.2 lbs) when combined with tirzepatide (p=0.001).
• Completed the Phase 1 DRAGON trial for SRK-181 in cancer, showing encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types, particularly clear cell renal cell carcinoma (ccRCC).
• Investigational New Drug (IND) application for SRK-439 cleared by the FDA, with plans to initiate dosing in healthy volunteers in Q4 2025.
• Extended cash runway into 2027, providing longer financial stability.
• Secured an additional $50.0 million in debt financing, increasing total outstanding debt to $100.0 million, and extended interest-only payment period to March 2029 and maturity date to February 1, 2030.

Negatives

• Significant increase in net loss for the three months ended September 30, 2025, to $102.2 million from $64.5 million in the prior year.
• Substantial increase in net loss for the nine months ended September 30, 2025, to $287.0 million from $179.8 million in the prior year.
• Received a Complete Response Letter (CRL) from the FDA in September 2025 for apitegromab's BLA, delaying potential commercialization.
• The CRL was due to observations identified during a routine general site inspection of a third-party fill-finish facility, which was issued a Form 483 and classified as Official Action Indicated (OAI).
• General and administrative expenses surged by 230.4% ($37.0 million) for the three months and 170.4% ($82.7 million) for the nine months ended September 30, 2025, driven by commercialization infrastructure and leadership change costs.
• Cash, cash equivalents, and marketable securities decreased by $67.6 million during the nine months ended September 30, 2025.
• Accumulated deficit grew to $1.2 billion as of September 30, 2025.
• Will cease to be a smaller reporting company as of January 1, 2026, leading to increased compliance costs and demands on management.
• 8,220,620 common warrants outstanding with an exercise price of $7.35 expire on December 31, 2025, potentially leading to further dilution if exercised or loss of potential capital if not.

Risks

• The regulatory approval process for product candidates is lengthy, time-consuming, and inherently unpredictable, with no guarantee of success.
• The Complete Response Letter (CRL) from the FDA in September 2025 for apitegromab's BLA has delayed progress toward potential commercialization and may lead to loss of competitive advantage, increased litigation, and other regulatory issues.
• The company has never commercialized a product and is building its compliance, medical affairs, and commercial organizations, which may not be successful.
• Changes or disruptions at the FDA and other government agencies could prevent timely review and approval of regulatory submissions.
• Product development is expensive and uncertain; additional costs or delays may occur in completing development and commercialization of apitegromab, SRK-181, SRK-439, or future candidates.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results, and interim data may change.
• Reliance on third parties to conduct clinical trials and preclinical studies poses risks if they fail to meet contractual duties, deadlines, or regulatory requirements.
• Preclinical programs may experience delays or never advance to clinical trials.
• Reliance on a limited number of third-party manufacturing and supply partners could lead to limited, interrupted, or unsatisfactory supply of materials.
• Reliance on third-party logistics, specialty distributors, specialty pharmacies, and patient service providers may subject the company to risks and substantial obligations.
• Need to continue growing the organization (personnel, systems, third-party relationships) to develop and commercialize product candidates, which may present management difficulties.
• Loss of key personnel or management transition.
• Failure to comply with healthcare privacy and data protection laws and regulations could lead to enforcement actions, litigation, and adverse publicity.
• Difficulty and cost in protecting intellectual property, with no guarantee of protection.
• Commercial success depends on operating without infringing third-party intellectual property rights; third-party claims could prevent or delay efforts.
• Incurred net losses since inception and anticipate continued losses, which could decrease company value and impair capital raising.
• Requires additional capital to fund operations; failure to obtain could halt development and commercialization.
• The price of the company's stock is volatile, and investors could lose all or part of their investment.
• No intention to pay dividends; returns limited to stock value appreciation.
• Management and affiliates own a significant percentage of stock, exerting control over stockholder approval matters.
• Cessation of smaller reporting company status on January 1, 2026, will increase costs and demands on management.
• Broad discretion in the use of existing cash, cash equivalents, and marketable securities, which may not be used effectively.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price and trading volume to decline.
• Risk of securities litigation, which is expensive and diverts management attention.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• Substantial number of warrants and equity awards could result in significant dilution.
• Changes in tax law, such as the OBBBA, could adversely affect the business and financial condition.
• Ability to use net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation under Section 382 of the Code.
• Adverse developments affecting the financial services industry could impact business operations and financial condition.
• Terms of the loan and security agreement place restrictions on operating and financial flexibility.
• Artificial intelligence presents risks and challenges, including security risks to confidential information, IP infringement, and increasing regulatory burden.
• Laws and regulations governing international operations (e.g., FCPA, export control) could negatively impact or restrict operations.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Current laboratory operations are concentrated in one location, posing risks from business interruptions or natural disasters.
• Coverage and reimbursement may be limited or unavailable for product candidates, if approved, making profitable sales difficult.
• EU drug marketing and reimbursement regulations may materially affect ability to market and receive coverage in European Member States.
• Inability to enter into or maintain collaborations could adversely affect the business.

Future Outlook

The company expects to continue incurring significant operating losses as it develops commercialization capabilities, continues apitegromab development (including ONYX and OPAL trials), advances its anti-myostatin program (SRK-439 Phase 1), discovers new product candidates, maintains its intellectual property, hires additional personnel, and builds public company infrastructure. It anticipates needing additional capital to complete clinical development and commercialization for its programs, despite current cash, cash equivalents, and marketable securities being sufficient into 2027. The company plans to resubmit the apitegromab BLA once the third-party fill-finish facility is reclassified by the FDA and expects to initiate commercial launch upon approval in applicable jurisdictions.

Management Comments

• Existing cash, cash equivalents and marketable securities at September 30, 2025 will be sufficient to fund current operations through at least a period of one year after the date these financial statements are issued.
• Expect to continue to incur significant expenses and operating losses for the foreseeable future in performing ongoing activities, including developing commercialization capabilities, continuing apitegromab development, advancing the anti-myostatin program, discovering additional product candidates, maintaining intellectual property, hiring personnel, and building public company infrastructure.
• Expect general and administrative expense to continue to be substantial as we continue to invest in building the infrastructure to support the commercialization of apitegromab.
• Expect that existing cash, cash equivalents, marketable securities and cash available to us as of September 30, 2025, will be sufficient to fund operating expenses and capital expenditure requirements into 2027.
• Will require additional capital in order to complete clinical development and commercialization for each of our current programs.

Industry Context

The biopharmaceutical industry is highly competitive, with many companies pursuing similar therapeutic areas. Scholar Rock operates in a rapidly changing environment, facing competition from companies with greater financial, technical, and human resources. The company's focus on the TGFβ superfamily and myostatin inhibition positions it in a niche with potential for first-in-class muscle-targeted treatments for rare diseases like SMA, but also faces competition from existing SMN-targeted therapies. The regulatory landscape is complex and subject to changes, including those related to drug pricing and data protection, which can impact commercial viability. The increasing use of AI also presents both opportunities and risks for the industry.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results in the context of global benchmarks.
• Many potential competitors, alone or with their strategic partners, have substantially greater financial, technical, and human resources, and significantly greater experience in drug discovery, development, regulatory approvals, and commercialization.
• For apitegromab in SMA, the company believes it has the potential to be the 'first muscle-targeted treatment that is aimed at improving motor function in patients with SMA who are receiving an SMN-targeted therapy,' competing with existing SMN-targeted treatments like nusinersen or risdiplam.
• The positive results for apitegromab in obesity (54.9% lean mass preservation) are presented as a significant finding (p=0.001) but without direct comparison to specific competitor obesity drugs or trials.
• SRK-181's 'encouraging responses' in anti-PD-(L)1 resistant cancer patients are noted as 'above what is expected from continuing PD-1 alone,' indicating a positive signal relative to standard of care continuation, but no specific competitor drug comparison is made.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings during the nine months ended September 30, 2025 and 2024.

Related Party Transactions

• No disclosed related party dealings.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises and warrant exercises; stock price volatility; impact from FDA delay on commercialization prospects; increased costs from losing smaller reporting company status.
• Employees: Increased headcount in commercial and field-facing teams; severance costs and equity award modifications due to 'leadership change' and 'separation agreements.'
• Patients (SMA): Delayed access to apitegromab due to FDA CRL; continued development of apitegromab in ongoing trials (ONYX, OPAL).
• Creditors (Oxford Finance LLC): Secured additional debt, extended interest-only period and maturity date, but also increased outstanding debt.
• Third-Party Manufacturers: One fill-finish facility received an OAI classification from the FDA, impacting the company's BLA resubmission.

Next Steps

• Resubmit the apitegromab BLA to the FDA once the third-party fill-finish facility has been reclassified.
• Initiate commercial product launch for apitegromab in applicable jurisdictions upon regulatory approval.
• Continue the ONYX long-term extension trial for apitegromab in SMA.
• Continue the Phase 2 OPAL trial for apitegromab in SMA patients under two years of age.
• Initiate dosing of SRK-439 in healthy volunteers in the fourth quarter of 2025.
• Continue to discover, validate, and develop additional product candidates through the proprietary platform.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional research, development, commercial, and other business personnel.
• Continue to build infrastructure to support operations as a public company.
• Cause Scholar Rock [***] to become a co-Borrower under the Loan Agreement or be dissolved with all assets and liabilities transferred to Borrower by April 30, 2026.
• Comply with additional disclosure and compliance requirements upon losing smaller reporting company status beginning with the Quarterly Report on Form 10-Q for Q1 2026.

Key Dates

Recommendation

The company has a promising pipeline with positive clinical data for apitegromab in SMA and obesity, and SRK-181 in cancer. The extended cash runway into 2027 provides some stability. However, the significant FDA Complete Response Letter for apitegromab, its lead candidate, introduces a material delay and uncertainty regarding commercialization. This regulatory setback, coupled with increasing operating losses and G&A expenses, creates a mixed outlook. Investors should hold to monitor the resolution of the FDA CRL and the progress of other pipeline assets, as the near-term commercialization prospects for apitegromab are now uncertain.

Keywords

Biopharmaceutical, SMA, Spinal Muscular Atrophy, Apitegromab, Myostatin, FDA, EMA, BLA, CRL, Clinical Trials, Oncology, Cancer, SRK-181, TGFβ1, SRK-439, Neuromuscular Disorders, Obesity, GLP-1 RA, Financial Results, 10-Q, Scholar Rock, Drug Development, Regulatory Approval, Commercialization, Orphan Drug, Fast Track, Rare Pediatric Disease, Priority Review